Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Mol Cancer Ther. 2008 Nov;7(11):3575–3585. doi: 10.1158/1535-7163.MCT-08-0640

Figure 6. TMZ pre-treatment enhances the synergistic effects of TMZ and S-TRAIL in TRAIL-resistant glioma cells.

Figure 6

Summary data showing the viability of U251 glioma cells following concomitant TMZ and S-TRAIL treatment, or following 24 h of TMZ sensitization. Cells were left untreated (ns) or sensitized (s) with TMZ for 24 h. Both sensitized and untreated cells were subsequently treated or re-treated with TMZ alone, control virus (AAV-Gluc-DsRed2: 4 000 MOI), S-TRAIL alone (Low: AAV-S-TRAIL=1 000 MOI, NSC-S-TRAIL=200 ng/mL; High: AAV-S-TRAIL=4 000 MOI, NSC-S-TRAIL=600 ng/mL), or a combination of TMZ and S-TRAIL for an additional 18 h at which time cell viability (A,B) or caspase 3/7 activation (C) were determined. Representative images and summary data of western blot analysis showing the expression of cleaved PARP (D) and immunocytochemical analysis of cleaved caspase-3 expression (E) in U251 cells following treatment with TMZ, NSC-S-TRAIL, concomitant TMZ and S-TRAIL, or TMZ and S-TRAIL following 24 h of TMZ sensitization. All data is normalized to control cells (TMZ 0 μM, AAV-Gluc-DsRed2 or S-TRAIL 0 ng/mL). *p<0.05 vs. S-TRAIL/TMZ no pretreatment.